Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Tech stocks are rallying on strong earnings and massive AI investment. Investors are watching Nvidia & hyperscaler spending for clues on how long it will last.
Sean Klitzner, showrunner and co-creator of Beast Games, previews the Feb. 25 finale packed with bigger stunts, wild twists, and the highest stakes yet.
Bob Sallmann, CFO of McGraw Hill, breaks down the quarter’s standout performance, digital expansion, and how AI tools are driving education innovation.
Daniel Desrochers, International Trade Reporter at POLITICO, joins us to break down the ruling, the billions at stake, and what it means for consumers.
